Summer animal and manufacturing update released
NewLimit reports first large-animal models, additional functional reprogramming payloads and scaled manufacturing. Full preclinical datasets were not provided in the update.
The dates describe events and disclosures, with links to their source. Recent additions were checked on 24 October 2026; older sources retain their original check dates.
50 developments
NewLimit reports first large-animal models, additional functional reprogramming payloads and scaled manufacturing. Full preclinical datasets were not provided in the update.
Company reports day-56 tolerability in three glaucoma participants, preliminary visual-field changes in two and approval to escalate dose. No controlled efficacy conclusion.
On 1 October the developer announced a planned 8 October presentation of early glaucoma-cohort findings. The subsequent results are recorded separately below.
A small placebo-controlled trial reported a liver histology result.
Australian registry records amendments to the Phase 1 study; registry update is not a result readout.
Insilico reports the start of dosing in GENESIS-IPF-3, identified as NCT07687459.
Ancillary analysis asks what proteomic changes in the existing trial indicate about ageing biology.
Company described expanded-access outcomes and revised study timing.
Lancet reports 271 days off dialysis, eventual pig-graft failure and a subsequent successful human kidney transplant in one patient.
Ten finalists received milestone awards; all twenty advanced.
Company describes late preclinical preparation and extension of AI prediction across cell types.
Life Biosciences announced the first administration in its Phase 1 trial.
Financing announcement says NewLimit plans its first reprogramming medicine's human study next year.
Retro’s financing and scientific update identifies RTR242 as its clinical-stage autophagy candidate.
Duplicated Supplementary Table 3 replaced; the publisher records the correction.
The FGF21 vector study reported cardiac and calcium findings in mice.
Nature includes the earlier online paper in its February issue.
The company announced FDA clearance to begin ER-100 human testing. Clearance to test is distinct from approval to market a treatment.
Revised competition rules increased the upper participant age limit to 90.
The primary experimental report becomes available.
A further mouse study examines tissue regeneration; the journal issue is January 2026.
Australian registry lists randomised single- and multiple-ascending-dose testing in healthy volunteers.
Shift describes work on calibrating how genetic-perturbation prediction models are evaluated.
A case report described the first recipient's kidney function.
eGenesis reported FDA clearance for a formal kidney study.
OpenAI and Retro report their model-to-laboratory protein-engineering work.
The board approved seeking dissolution and the company closed out ASPIRE.
Laboratory manuscript reports single-factor molecular rejuvenation experiments.
Nature Medicine reports the 71-participant randomised IPF study.
Forty Healthspan teams were selected as milestone winners from the earlier qualifying cohort.
Week-36 findings were reported alongside the missed primary time-window comparison and strategic review.
Company reported the board's recommendation to continue and escalate.
Company year-in-review reports transcription-factor discoveries and animal liver-disease work.
Retro says RTR242 reached first-in-human dosing during 2025; no efficacy outcome follows from dosing alone.
Life Biosciences reported further NAION-like injury-model results at AAO.
The randomised trial added a negative primary result.
CIRM announced an award supporting development of RJB-0402.
LyGenesis announced the start of human dosing.
Nature Biotechnology documents AI-assisted target selection and molecular generation alongside experimental validation.
Research extends the approach into natural-ageing and preventive mouse experiments.
Nature paper documented donor edits and nonhuman-primate testing.
NewLimit explains its combination of single-cell genomics, pooled screens and machine learning.
OSK research connected molecular reprogramming with retinal function in experimental mice.
The paper described ectopic liver tissue after hepatocyte transplantation.
UNITY's annual filing records the start of the first human study.
Cell and mouse experiments establish the senolytic CAR T approach.
Researchers reported changes in senescence-associated markers.
Academic experiments later cited by Altos test brief reprogramming in cells and mouse models.
Cell and animal experiments established the combination's research rationale.
No developments match this field.